First human trial in China cuts epilepsy seizures by 92.6 per cent
In short
- Around one-third of epilepsy patients worldwide do not respond to existing medications.
- The first human trial of a chemogenetic approach reported a 92.6 per cent cut in seizures.
- Traditional resection surgery can carry the risk of irreversible neurological damage.
Why it's good news
About a third of people with epilepsy do not respond to existing medicines, and surgery carries serious risks. This first human trial tested a chemogenetic approach, which uses drugs to switch targeted brain cells off. The work is at an early stage, so it will need wider testing before it reaches patients routinely.
From South China Morning Post
For people living with refractory epilepsy, the brain is like a city that can suffer a blackout any time lightning strikes. Without warning, an abnormal neural discharge can sweep through the intracranial circuits, leaving behind convulsions, loss of consciousness and years of lingering panic. Around one-third of epilepsy patients worldwide are completely unresponsive to existing medications, while traditional craniotomy resection surgery often carries the risk of irreversible neurological...